The definitive guide to gene editing.
★
Menu
Home Learn News Ask the Atlas
Explore Technologies Diseases Treatments Clinical Trials Companies Scientists Genes Research Institutions
Beyond medicine Agriculture Ethics Investing World map
Learn & Tools Start here Glossary A–Z Compare technologies Timeline Lists & Rankings AI Agents ★ Saved API
About About us Methodology Data Sources Editorial Policy Contact Disclaimers

🧭 Guided View
New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.

⚡ Expert View
You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.

Interface language
Light mode

Treatment · Cancer

CTX112

An allogeneic CD19 CAR-T candidate with multiple CRISPR edits intended to make one donor's cells usable in many patients.

Phase I/II cell therapyallogeneicCAR-T
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Simple explanation

Ordinary CAR-T therapy is made individually from each patient's own cells, which takes weeks and costs a great deal. CTX112 starts from a healthy donor instead and uses several simultaneous CRISPR edits to stop the donor cells attacking the patient and to slow the patient's immune system destroying them — so one batch can serve many people, off the shelf.

Go deeper

CTX112 is an allogeneic anti-CD19 CAR-T candidate from CRISPR Therapeutics incorporating multiple edits to remove the endogenous T-cell receptor and MHC class I, plus potency edits intended to improve persistence. It is in trials in B-cell malignancies and has been explored in autoimmune indications; it holds FDA Regenerative Medicine Advanced Therapy designation.

Sources

Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

CancerLeukemia and Lymphoma

Clinical Trials

A Study of CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Genes

B2MTRAC

Companies

CRISPR Therapeutics
Educational information only This page is a reference, not medical advice. Research and regulatory status change; check the last-updated date above and confirm anything important against the primary sources listed.